...
search icon
rcus-img

Arcus Biosciences Inc Share Price

RCUS
NYQ
$22.7
-$1.72
(-7.04%)
1D
Industry: Biotechnology Sector: Health Care

Arcus Biosciences Inc Analyst Forecast

Arcus Biosciences Inc Share Price Chart

Arcus Biosciences Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.06B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.15M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.92
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.5 L
$26.4 H
$22.7

About Arcus Biosciences Inc, Common Stock

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California. more

Industry: BiotechnologySector: Health Care

Arcus Biosciences Inc Stock Returns

Time FrameRCUSSectorS&P500
1-Week Return2.21%-0.69%-0.76%
1-Month Return13.73%-2.02%-0.71%
3-Month Return5.43%-0.79%-0.77%
6-Month Return97.05%10.67%2.91%
1-Year Return134.02%5.71%21.07%
3-Year Return32.21%21.98%75.67%
5-Year Return-37.72%33.38%71.66%
10-Year Return33.53%123.79%234.96%

Arcus Biosciences Inc Financials

Dec '21Dec '22Dec '23Dec '24Dec '255YR TREND
Total Revenue383.00M112.00M117.00M258.00M247.00M[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":29.24,"profit":true},{"date":"2023-12-31","value":30.55,"profit":true},{"date":"2024-12-31","value":67.36,"profit":true},{"date":"2025-12-31","value":64.49,"profit":true}]
Cost of Revenue7.06M14.00M340.00M10.00M10.00M[{"date":"2021-12-31","value":2.08,"profit":true},{"date":"2022-12-31","value":4.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":2.94,"profit":true},{"date":"2025-12-31","value":2.94,"profit":true}]
Gross Profit383.00M112.00M117.00M258.00M237.00M[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":29.24,"profit":true},{"date":"2023-12-31","value":30.55,"profit":true},{"date":"2024-12-31","value":67.36,"profit":true},{"date":"2025-12-31","value":61.88,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%95.95%[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":95.95,"profit":true}]
Operating Expenses329.00M392.00M457.00M588.00M623.00M[{"date":"2021-12-31","value":52.81,"profit":true},{"date":"2022-12-31","value":62.92,"profit":true},{"date":"2023-12-31","value":73.35,"profit":true},{"date":"2024-12-31","value":94.38,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Operating Income54.00M(280.00M)(340.00M)(330.00M)(386.00M)[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-518.52,"profit":false},{"date":"2023-12-31","value":-629.63,"profit":false},{"date":"2024-12-31","value":-611.11,"profit":false},{"date":"2025-12-31","value":-714.81,"profit":false}]
Total Non-Operating Income/Expense1.40M28.00M78.00M95.00M66.00M[{"date":"2021-12-31","value":1.47,"profit":true},{"date":"2022-12-31","value":29.47,"profit":true},{"date":"2023-12-31","value":82.11,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":69.47,"profit":true}]
Pre-Tax Income55.00M(266.00M)(301.00M)(283.00M)(353.00M)[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-483.64,"profit":false},{"date":"2023-12-31","value":-547.27,"profit":false},{"date":"2024-12-31","value":-514.55,"profit":false},{"date":"2025-12-31","value":-641.82,"profit":false}]
Income Taxes2.00M1.00M6.00M1.00M-[{"date":"2021-12-31","value":33.33,"profit":true},{"date":"2022-12-31","value":16.67,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":16.67,"profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income After Taxes53.00M(267.00M)(307.00M)(284.00M)-[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-503.77,"profit":false},{"date":"2023-12-31","value":-579.25,"profit":false},{"date":"2024-12-31","value":-535.85,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Income From Continuous Operations52.83M(267.00M)(307.00M)(284.00M)(353.00M)[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-505.39,"profit":false},{"date":"2023-12-31","value":-581.11,"profit":false},{"date":"2024-12-31","value":-537.57,"profit":false},{"date":"2025-12-31","value":-668.18,"profit":false}]
Income From Discontinued Operations-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income53.00M(267.00M)(307.00M)(283.00M)(353.00M)[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-503.77,"profit":false},{"date":"2023-12-31","value":-579.25,"profit":false},{"date":"2024-12-31","value":-533.96,"profit":false},{"date":"2025-12-31","value":-666.04,"profit":false}]
EPS (Diluted)0.43(3.72)(4.15)(3.10)(3.30)[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-865.12,"profit":false},{"date":"2023-12-31","value":-965.12,"profit":false},{"date":"2024-12-31","value":-720.93,"profit":false},{"date":"2025-12-31","value":-767.44,"profit":false}]

Arcus Biosciences Inc Ratios

Arcus Biosciences Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

RCUS
Cash Ratio 4.25
Current Ratio 4.36

Arcus Biosciences Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RCUS
ROA (LTM) -21.08%
ROE (LTM) -63.26%

Arcus Biosciences Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RCUS
Debt Ratio Lower is generally better. Negative is bad. 0.45
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.55

Arcus Biosciences Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RCUS
Trailing PE NM
Forward PE NM
P/S (TTM) 12.39
P/B 4.85
Price/FCF NM
EV/R 8.87
EV/Ebitda 3.96

FAQs

What is Arcus Biosciences Inc share price today?

Arcus Biosciences Inc (RCUS) share price today is $22.7

Can Indians buy Arcus Biosciences Inc shares?

Yes, Indians can buy shares of Arcus Biosciences Inc (RCUS) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RCUS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Arcus Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Arcus Biosciences Inc (RCUS) via the Vested app. You can start investing in Arcus Biosciences Inc (RCUS) with a minimum investment of $1.

How to invest in Arcus Biosciences Inc shares from India?

You can invest in shares of Arcus Biosciences Inc (RCUS) via Vested in three simple steps:

  • Click on Sign Up or Invest in RCUS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Arcus Biosciences Inc shares
What is Arcus Biosciences Inc 52-week high and low stock price?

The 52-week high price of Arcus Biosciences Inc (RCUS) is $26.4. The 52-week low price of Arcus Biosciences Inc (RCUS) is $6.5.

What is Arcus Biosciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Arcus Biosciences Inc (RCUS) is

What is Arcus Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Arcus Biosciences Inc (RCUS) is 4.85

What is Arcus Biosciences Inc dividend yield?

The dividend yield of Arcus Biosciences Inc (RCUS) is 0.00%

What is the Market Cap of Arcus Biosciences Inc?

The market capitalization of Arcus Biosciences Inc (RCUS) is $3.06B

What is Arcus Biosciences Inc's stock symbol?

The stock symbol (or ticker) of Arcus Biosciences Inc is RCUS

How Can Investors Use Arcus Biosciences Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Arcus Biosciences Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Arcus Biosciences Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Arcus Biosciences Inc shares for Indian investors?

When investing in Arcus Biosciences Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Arcus Biosciences Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Arcus Biosciences Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Arcus Biosciences Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Arcus Biosciences Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top